Compare KLTR & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KLTR | SPRO |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.0M | 135.5M |
| IPO Year | 2021 | 2017 |
| Metric | KLTR | SPRO |
|---|---|---|
| Price | $1.51 | $2.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 510.3K | 408.3K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 61.90 | ★ 111.81 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $180,854,000.00 | $66,802,000.00 |
| Revenue This Year | $2.96 | N/A |
| Revenue Next Year | $4.96 | $300.00 |
| P/E Ratio | ★ N/A | $16.23 |
| Revenue Growth | 1.20 | ★ 39.24 |
| 52 Week Low | $1.06 | $0.65 |
| 52 Week High | $2.27 | $3.09 |
| Indicator | KLTR | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 63.10 | 56.63 |
| Support Level | $1.39 | $2.15 |
| Resistance Level | $1.63 | $2.70 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 82.00 | 85.53 |
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.